Robert W. Baird cut shares of Trius Therapeutics (NASDAQ:TSRX) from an outperform rating to a neutral rating in a research report sent to investors on Wednesday morning, TheFlyOnTheWall.com reports. The firm currently has $14.00 price target on the stock, up from their previous price target of $13.00.
Trius Therapeutics (NASDAQ:TSRX) traded down 0.43% on Wednesday, hitting $13.76. Trius Therapeutics has a 1-year low of $4.41 and a 1-year high of $14.17. The stock’s 50-day moving average is currently $9.79. The company’s market cap is $658.7 million.
Separately, analysts at Guggenheim initiated coverage on shares of Trius Therapeutics in a research note to investors on Friday, May 10th. They set a buy rating and a $20.00 price target on the stock.
Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Trius Therapeutics has a consensus rating of Hold and an average target price of $11.97.
Trius Therapeutics, Inc operates as a biopharmaceutical research company. It has a cooperative research and development agreement with Lawrence Livermore National Security LLC for the research and development of gram-negative biodefense pathogens; and a license agreement with Dong-A Pharmaceutical Co, Ltd.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.